The Phosphotyrosine Interactome of the Insulin Receptor Family and Its Substrates IRS-1 and IRS-2*S
- From the Department of Proteomics and Signal Transduction, Max-Planck-Institute for Biochemistry, Am Klopferspitz 18, 82152 Martinsried, Munich, Germany
- ‡To whom correspondence should be addressed. Tel.: 49-89-8578-2557; Fax: 49-89-8578-2219; E-mail: mmann{at}biochem.mpg.de
Abstract
The insulin signaling pathway is critical in regulating glucose levels and is associated with diabetes, obesity, and longevity. A tyrosine phosphorylation cascade creates docking sites for protein interactions, initiating subsequent propagation of the signal throughout the cell. The phosphotyrosine interactome of this medically important pathway has not yet been studied comprehensively. We therefore applied quantitative interaction proteomics to exhaustively profile all potential phosphotyrosine-dependent interaction sites in its key players. We targeted and compared insulin receptor substrates 1 and 2 (IRS-1 and IRS-2) as central distributors of the insulin signal, the insulin receptor, the insulin-like growth factor 1 receptor, and the insulin receptor-related receptor. Using the stable isotope labeling by amino acids in cell culture (SILAC) approach with phosphorylated versus non-phosphorylated bait peptides, we found phosphorylation-specific interaction partners for 52 out of 109 investigated sites. In addition, doubly and triply phosphorylated motifs provided insight into the combinatorial effects of phosphorylation events in close proximity to each other. Our results retrieve known interactions and substantially broaden the spectrum of potential interaction partners of IRS-1 and IRS-2. A large number of common interactors rationalize their extensive functional redundancy. However, several proteins involved in signaling and metabolism interact differentially with IRS-1 and IRS-2 and thus provide leads into their different physiological roles. Differences in interactions at the receptor level are reflected in multisite recruitment of SHP2 by the insulin-like growth factor 1 receptor and limited but exclusive interactions with the IRR. In common with other recent reports, our data furthermore hint at non-SH2 or phosphotyrosine-binding domain-mediated phosphotyrosine binding.
Footnotes
-
Published, MCP Papers in Press, November 11, 2008, DOI 10.1074/mcp.M800407-MCP200
-
↵1 The abbreviations used are: SH2, Src homology 2; PH, pleckstrin homology; MS, mass spectrometry; Csk, C-terminal Src-kinase; Tyr(P), phosphotyrosine; LC, liquid chromatography; E2, ubiquitin carrier protein; E3, ubiquitin-protein isopeptide ligase; MS/MS, tandem mass spectrometry; PLCγ, phospholipase C gamma; LTQ, linear quadrupole ion trap; SILAC, stable isotope labeling by amino acids in cell culture; PI3K, phosphatidylinositol-3-kinase; Arg, arginine; Lys, lysine; PTB, phosphotyrosine binding; IRS, insulin receptor substrate; InsR, insulin receptor; IGF1R, insulin-like growth factor 1 receptor; IRR, insulin receptor-related receptor; IGF, insulin-like growth factor; MAP, mitogen-activated protein; ErbB, epidermal growth factor family of receptor tyrosine kinases; Crk, chicken tumor virus no. 10 regulator of kinase; NPEY, Asn-Pro-Glu-Tyr.
-
↵* This work was supported, in whole or in part, by National Institutes of Health Grant DK 60837 through the Diabetes Genome Anatomy Project consortium. This work was also supported by Interaction Proteome, a 6th Framework program of the European Commission.
-
↵S The on-line version of this article (available at http://www.mcp.org) contains supplemental material.
-
- Received August 29, 2008.
- Revision received November 7, 2008.
- © 2009 The American Society for Biochemistry and Molecular Biology











